MaineCare Services
An Office of the Department of Health and Human Services
Paul R. LePage, Governor
Ricker Hamilton, Commissioner

Department of Health and Human Services
MaineCare Services
11 State House Station
Augusta, Maine 04333-0011
Tel.: (207) 287-2674; Fax: (207) 287-2675
TTY Users: Dial 711 (Maine Relay)

DUR COMMITTEE AGENDA

Date: Tuesday, June 12, 2018
Time: 5:30PM to 8:30PM
Location: Augusta Armory, 179 Western Avenue, Augusta, ME

1) Call to Order

2) Introductions

3) MaineCare Updates

4) Public Comments

5) Old Business
   - Review of Minutes

6) Closed Session
   - Drug Financial Information Review

7) New Business (open session)

- Retro-DUR
  - Introduction: Use of Naloxone Intolerance

- Retro-DUR
  - Data presentation: Statin Use in ASCVD

- Updated Suboxone PA form

- Theraputic Drug Class Review
  Phosphate Binders, Non-Calcium

- New Drug Review

Aimovig	Lonhala	Steglujan
Carospir	Luxturna	Symdeko
Cimduo	Lyrica CR	Symfi
Crysvita	Noctiva	Symfi Lo
Daxbia	Osmolex ER	Trogarzo
Erleada	Rhopressa	Xhance
Gocovri	Segluromet	Zilretta

- FDA Safety Alerts
  Risk of serious and potentially fatal blood disorder prompts FDA action on oral over-the-counter benzocaine products used for teething and mouth pain and prescription local anesthetics
  https://www.fda.gov/Drugs/DrugSafety/ucm608265.htm

  Lamictal (lamotrigine): Drug Safety Communication - Serious Immune System Reaction
  https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm605628.htm

Juluca, Tivicay, Triumeq (dolutegravir): FDA to Evaluate - Potential Risk of Neural Tube Birth Defects
https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm608168.htm?utm_campaign=FDA%20MedWatch%20-%20Juluca%2C%20Tivicay%2C%20Triumeq&utm_medium=email&utm_source=Eloqua

Keytruda (pembrolizumab) or Tecentriq (atezolizumab): FDA Alerts Health Care Professionals and Investigators: FDA Statement - Decreased Survival in Some Patients in Clinical Trials Associated with Monotherapy
https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm608253.htm

- Next Meeting (Tuesday, September 11, 2018 from 5:30pm to 8:30pm)
- Adjournment: 8:30PM